These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 39048767)

  • 1. Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance.
    Wellhausen N; Baek J; Gill SI; June CH
    Nat Rev Cancer; 2024 Sep; 24(9):614-628. PubMed ID: 39048767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T-cell-based Immunotherapies for Haematological Cancers, Part B: A SWOT Analysis of Adoptive Cell Therapies.
    Rallis KS; Hillyar CRT; Sideris M; Davies JK
    Anticancer Res; 2021 Mar; 41(3):1143-1156. PubMed ID: 33788705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy.
    Li YR; Zhou Y; Yu J; Zhu Y; Lee D; Zhu E; Li Z; Kim YJ; Zhou K; Fang Y; Lyu Z; Chen Y; Tian Y; Huang J; Cen X; Husman T; Cho JM; Hsiai T; Zhou JJ; Wang P; Puliafito BR; Larson SM; Yang L
    Mol Ther; 2024 Jun; 32(6):1849-1874. PubMed ID: 38584391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering Hematopoietic Cells for Cancer Immunotherapy: Strategies to Address Safety and Toxicity Concerns.
    Resetca D; Neschadim A; Medin JA
    J Immunother; 2016 Sep; 39(7):249-59. PubMed ID: 27488725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.
    Sloas C; Gill S; Klichinsky M
    Front Immunol; 2021; 12():783305. PubMed ID: 34899748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematopoietic stem cells for cancer immunotherapy.
    Gschweng E; De Oliveira S; Kohn DB
    Immunol Rev; 2014 Jan; 257(1):237-49. PubMed ID: 24329801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance.
    Chandran SS; Klebanoff CA
    Immunol Rev; 2019 Jul; 290(1):127-147. PubMed ID: 31355495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fully equipped CARs to address tumor heterogeneity, enhance safety, and improve the functionality of cellular immunotherapies.
    Alviano AM; Biondi M; Grassenis E; Biondi A; Serafini M; Tettamanti S
    Front Immunol; 2024; 15():1407992. PubMed ID: 38887285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors.
    Baybutt TR; Flickinger JC; Caparosa EM; Snook AE
    Clin Pharmacol Ther; 2019 Jan; 105(1):71-78. PubMed ID: 30406956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering immune-evasive allogeneic cellular immunotherapies.
    Martin KE; Hammer Q; Perica K; Sadelain M; Malmberg KJ
    Nat Rev Immunol; 2024 Sep; 24(9):680-693. PubMed ID: 38658708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers.
    Inthagard J; Edwards J; Roseweir AK
    Clin Sci (Lond); 2019 Jan; 133(2):181-193. PubMed ID: 30659159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T Cell Receptors for Gene Transfer in Adoptive T Cell Therapy.
    Sharma P; Kranz DM
    Crit Rev Immunol; 2019; 39(2):105-122. PubMed ID: 31679251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAR-Ts: new perspectives in cancer therapy.
    Abrantes R; Duarte HO; Gomes C; Wälchli S; Reis CA
    FEBS Lett; 2022 Feb; 596(4):403-416. PubMed ID: 34978080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tuning the performance of CAR T cell immunotherapies.
    Richardson NH; Luttrell JB; Bryant JS; Chamberlain D; Khawaja S; Neeli I; Radic M
    BMC Biotechnol; 2019 Nov; 19(1):84. PubMed ID: 31783836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.
    Shum T; Kruse RL; Rooney CM
    Expert Opin Biol Ther; 2018 Jun; 18(6):653-664. PubMed ID: 29727246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
    Hong M; Clubb JD; Chen YY
    Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons.
    Zhao Q; Jiang Y; Xiang S; Kaboli PJ; Shen J; Zhao Y; Wu X; Du F; Li M; Cho CH; Li J; Wen Q; Liu T; Yi T; Xiao Z
    Front Immunol; 2021; 12():658753. PubMed ID: 33859650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
    Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
    Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy Using Chimeric Antigen Receptor-Engineered T Cells: A Novel Cellular Therapy with Important Implications for the Clinical Laboratory.
    Thibodeaux SR; Milone MC
    Clin Chem; 2019 Apr; 65(4):519-529. PubMed ID: 30593467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-Cell Gene Therapy in Cancer Immunotherapy: Why It Is No Longer Just CARs on The Road.
    Crowther MD; Svane IM; Met Ö
    Cells; 2020 Jun; 9(7):. PubMed ID: 32630096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.